NEW YORK, March 21, 2017 /PRNewswire/ --
Today at Stock-Callers.com, investors' attention is directed to four equities in the Medical Appliances and Equipment space, and they are: EnteroMedics Inc. (NASDAQ: ETRM), Abbott Laboratories (NYSE: ABT), Boston Scientific Corp. (NYSE: BSX), and Medtronic PLC (NYSE: MDT). These companies operate in the Healthcare sector, which saw its losses widen slightly in afternoon trade on Monday, March 20th, 2017, with the NYSE Health Care Index declining 0.1%, while shares of health care companies in the S&P 500 were down about 0.2% as a group. Download the free research reports on these stocks today:
St. Paul, Minnesota headquartered EnteroMedics Inc.'s shares fell 1.83%, closing Monday's trading session at $5.90. The stock recorded a trading volume of 252,697 shares. Shares of the Company have skyrocketed 9,493.50% over the previous three months and 195.00% since the start of this year. The stock is trading 172.41% above its 200-day moving average. Additionally, shares of EnteroMedics, which focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders, have a Relative Strength Index (RSI) of 42.03.
On March 07th, 2017, the Company reported sales of $141,900, gross profits totaling $52,500, and a net loss of $4.4 million, or $2.65 per share, including selling, general, and administrative expenses of $2.9 million and research and development expenses of $1.3 million for Q4 2016. On December 31st, 2016, the Company's cash, cash equivalents, and short-term investments totaled $3.3 million. See our free and comprehensive research report on ETRM at:
On Monday, shares in Abbott Park, Illinois headquartered Abbott Laboratories recorded a trading volume of 3.51 million shares. The stock declined 0.46%, ending the day at $44.98. The Company's shares have advanced 1.76% in the past month, 16.29% in the last three months, and 17.86% over the previous one year. The stock is trading above its 50-day and 200-day moving averages by 4.42% and 9.61%, respectively. Furthermore, shares of Abbott Laboratories, which manufactures and sells health care products worldwide, have an RSI of 56.40.
On March 01st, 2017, research firm RBC Capital Markets reiterated its 'Outperform' rating on the Company's stock with an increase of the target price from $46 a share to $50 a share.
On March 18th, 2017, Abbott announced favorable one-year outcomes from the largest study of real-world experience for the MitraClip system in transcatheter mitral valve repair procedures in the US. MitraClip treats people with degenerative mitral regurgitation (DMR, also known as leaky heart valve), a serious condition involving a dysfunction of the heart's mitral valve, which regulates blood flow into the heart's main pumping chamber. The study analyzed data from the Transcatheter Valve Therapy registry involving nearly 3,000 DMR patients who were high-risk for surgery. ABT free research report PDF is just a click away at:
Marlborough, Massachusetts headquartered Boston Scientific Corp.'s stock finished the day 0.16% lower at $24.39 with a total trading volume of 3.70 million shares. Shares of the Company have advanced 14.72% in the previous three months and 12.76% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 0.05% and 5.06%, respectively. Additionally, shares of Boston Scientific, which develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide, have an RSI of 45.44.
On March 16th, 2017, Boston announced that the National Institute for Health and Care Excellence issued medical technology guidance recommending the use of Boston Scientific Corporation cardiac resynchronization therapy defibrillators powered by EnduraLife™ Battery Technology for treating patients with heart failure. Sign up for your complimentary report on BSX at:
Shares in Dublin, Ireland headquartered Medtronic PLC ended yesterday's session 0.99% lower at $81.42. The stock recorded a trading volume of 4.39 million shares. The Company's shares have advanced 4.40% in the last one month, 11.53% over the previous three months, and 14.31% since the start of this year. The stock is trading 4.62% above its 50-day moving average. Moreover, shares of Medtronic, which manufactures and sells device-based medical therapies worldwide, have an RSI of 55.22.
On February 22nd, 2017, research firm Needham reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $84 a share to $91 a share.
On March 17th, 2017, Medtronic announced first-ever clinical data from the Surgical Replacement and Transcatheter Aortic Valve Implantation Trial, which was presented at the American College of Cardiology 66th Annual Scientific Session and published simultaneously in The New England Journal of Medicine. Data from the trial showed the Medtronic self-expanding TAVR platform met its primary endpoint of all-cause mortality or disabling stroke at two years. Register for free on Stock-Callers.com and download the latest research report on MDT at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA